FDA Plans to Make Rare Disease Drug Review Faster and More Efficient

On October 14, 2026, the U.S. Food and Drug Administration (FDA) released a white paper introducing its Rare Disease Framework Initiative, calling for “fit-for-purpose” evidence to be the norm for every rare disease application. In plain terms, the evidence it asks for would match what can realistically be collected from very small patient populations while holding firm to safety and effectiveness standards….
By: Stinson LLP